+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Wound Care Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 115 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5176853

Wound care biologics is gaining popularity for the treatment of wounds and burn injuries. Factors, such as growing burden of burn injuries, increasing burden of diabetic foot ulcers, and government initiatives regarding wound care treatment are driving the growth of the wound care biologics market.

Key Highlights

  • The incidence of diabetes among all ages is increasing, mainly due to obesity, unhealthy diet, and physical inactivity. According to the International Diabetes Federation, in 2019, there were around 4.2 million deaths globally due to diabetes.
  • The incidence of chronic wounds, especially foot ulcers is increasing among the diabetic population, resulting in the increased usage of wound care biologics products. Therefore, the growing focus toward the development of better treatment options, along with the huge burden of diseases, is expected to drive the wound care biologics market. However, the high treatment cost is expected to restrain the growth of the global market in the forecast period.

Key Market Trends

The Biological Skin Substitutes Segment is Expected to Witness Better Growth Over the Forecast Period

Based on products, the market is segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is expected to witness better growth due to their wide usage in the treatment of chronic wounds. These skin substitutes have an intact extracellular matrix for structural support. Biological skin substitutes are majorly recommended for burn injuries and treatment of chronic wounds, such as diabetic foot ulcers and venous leg ulcers. According to the International Diabetes Federation, in 2019, almost 463 million people (20-79 years) had diabetes, and by 2045, this is expected to rise to 700 million. Chronic wounds lead to complications, such as infection, ulceration, and insufficient blood supply. Hence, the increasing burden of diabetes and the growing adoption of these products are the major factors propelling the growth of the wound care biologics market.

North America Dominates the Wound Care Biologics Market

North America is expected to dominate the wound care biologics market during the forecast years. This is mainly attributed to the growing diabetic population and the rising number of burn injury cases in the region. According to the American Burn Association, approximately 450,000 patients receive hospital and emergency room treatment for burns each year. Burn injury is one of the leading causes of unintentional death in the United States, which leads to increased adoption of wound care biologics by the hospitals or clinics. Hence, increased awareness, rapid adoption of new technologies, and increasing chronic wound cases are expected to positively impact market growth in this region.

Competitive Landscape

The wound care biologics market is competitive and many of the global players are in the market. For instance, ACell Inc., Integra LifeSciences Corporation, Kerecis, Marine Polymer Technologies Inc., MiMedx Inc., Misonix, Inc., Mölnlycke Health Care, Smith & Nephew PLC, and Wright Medical Group NV are providing these products across the world.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Burn Injuries and Road Accidents
4.2.2 Government Initiatives Regarding Wound Care Treatment
4.3 Market Restraints
4.3.1 High Treatment Cost
4.3.2 Stringent Regulatory Guidelines and Challenges Faced by the Manufacturers
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Biological Skin Substitutes
5.1.2 Topical Agents
5.2 By Wound Type
5.2.1 Ulcers Diabetic Foot Ulcers Venous Ulcers Pressure Ulcers Other Ulcers
5.2.2 Surgical and Traumatic Wounds
5.2.3 Burns
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 ACell Inc.
6.1.2 Integra LifeSciences Corporation
6.1.3 Kerecis
6.1.4 Marine Polymer Technologies Inc.
6.1.5 MiMedx Inc.
6.1.6 MISONIX Inc.
6.1.7 Molnlycke Health Care
6.1.8 Smith & Nephew PLC
6.1.9 Wright Medical Group NV

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ACell Inc.
  • Integra LifeSciences Corporation
  • Kerecis
  • Marine Polymer Technologies Inc.
  • MiMedx Inc.
  • MISONIX Inc.
  • Molnlycke Health Care
  • Smith & Nephew PLC
  • Wright Medical Group NV